Media, investigators, organizations issuing press releases, and others with access to research accepted for presentation during CTO Plus 2025 are required to abide by the embargo policies governing CRF® meetings.
The Cardiovascular Research Foundation® embargoes information presented as a late-breaking clinical trial, late-breaking clinical science, or featured clinical research. Coverage of these studies is strictly prohibited until the start time of each trial’s official presentation as listed in the CTO Plus 2025 Program on the official CTO Plus website. No journalist, exhibitor, or university (or affiliated organization or company) may disseminate information until the trial’s official presentation time. All embargo times are listed in Eastern Standard Time (EST). There is no official embargo for research presented as an abstract, challenging case, or during an innovation session. However, to maximize the impact of your presentation we recommend that no data be shared until the start of CTO Plus 2025 and ideally not before your formal presentation.
For questions regarding the embargo policy, please email [email protected].
